Ameriprise Financial Inc. Purchases 174,400 Shares of West Pharmaceutical Services, Inc. (WST)

Ameriprise Financial Inc. lifted its position in West Pharmaceutical Services, Inc. (NYSE:WST) by 43.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 575,409 shares of the medical instruments supplier’s stock after acquiring an additional 174,400 shares during the quarter. Ameriprise Financial Inc. owned 0.78% of West Pharmaceutical Services worth $54,387,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Dorsey Wright & Associates raised its holdings in shares of West Pharmaceutical Services by 1.1% in the second quarter. Dorsey Wright & Associates now owns 28,139 shares of the medical instruments supplier’s stock valued at $2,660,000 after acquiring an additional 318 shares in the last quarter. TIAA CREF Investment Management LLC raised its holdings in West Pharmaceutical Services by 15.3% in the second quarter. TIAA CREF Investment Management LLC now owns 168,675 shares of the medical instruments supplier’s stock worth $15,943,000 after purchasing an additional 22,363 shares in the last quarter. Teachers Advisors LLC raised its holdings in West Pharmaceutical Services by 10.2% in the second quarter. Teachers Advisors LLC now owns 76,366 shares of the medical instruments supplier’s stock worth $7,218,000 after purchasing an additional 7,092 shares in the last quarter. Seven Eight Capital LP raised its holdings in West Pharmaceutical Services by 282.9% in the second quarter. Seven Eight Capital LP now owns 13,400 shares of the medical instruments supplier’s stock worth $1,267,000 after purchasing an additional 9,900 shares in the last quarter. Finally, Riverhead Capital Management LLC raised its holdings in West Pharmaceutical Services by 66.5% in the second quarter. Riverhead Capital Management LLC now owns 2,830 shares of the medical instruments supplier’s stock worth $268,000 after purchasing an additional 1,130 shares in the last quarter. Hedge funds and other institutional investors own 90.57% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://ledgergazette.com/2017/09/21/ameriprise-financial-inc-purchases-174400-shares-of-west-pharmaceutical-services-inc-wst.html.

Shares of West Pharmaceutical Services, Inc. (WST) opened at 94.68 on Thursday. The stock’s 50 day moving average price is $87.78 and its 200-day moving average price is $89.57. The stock has a market cap of $7.01 billion, a price-to-earnings ratio of 40.64 and a beta of 1.13. West Pharmaceutical Services, Inc. has a 52 week low of $70.17 and a 52 week high of $99.91.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.01. The company had revenue of $397.60 million for the quarter, compared to analyst estimates of $406.00 million. West Pharmaceutical Services had a return on equity of 14.02% and a net margin of 11.42%. West Pharmaceutical Services’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.59 EPS. Equities analysts anticipate that West Pharmaceutical Services, Inc. will post $2.68 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Wednesday, October 18th will be given a $0.14 dividend. The ex-dividend date of this dividend is Tuesday, October 17th. This represents a $0.56 dividend on an annualized basis and a yield of 0.59%. This is a positive change from West Pharmaceutical Services’s previous quarterly dividend of $0.13. West Pharmaceutical Services’s dividend payout ratio (DPR) is currently 22.22%.

A number of equities analysts have commented on the stock. Jefferies Group LLC reiterated a “hold” rating and issued a $90.00 target price on shares of West Pharmaceutical Services in a report on Thursday, June 8th. Zacks Investment Research upgraded shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating and set a $114.00 target price for the company in a report on Friday, June 9th. Finally, BidaskClub downgraded shares of West Pharmaceutical Services from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 13th. Two equities research analysts have rated the stock with a sell rating and three have issued a buy rating to the stock. West Pharmaceutical Services currently has a consensus rating of “Hold” and a consensus target price of $98.52.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply